Adam L. Boxer

MD PhD

Neurologist
International leader in treating atypical parkinsonism

Dr. Adam Boxer is a neurologist at the UCSF Memory and Aging Center who specializes in Alzheimer's disease, frontotemporal dementia and atypical parkinsonism – in particular, corticobasal degeneration and progressive supranuclear palsy.

Boxer obtained his medical and doctoral degrees as part of the Medical Scientist Training Program at New York University School of Medicine, a program funded by the National Institutes of Health. He completed a residency in neurology at Stanford University Medical Center and a fellowship in behavioral neurology at UCSF.

Boxer directs the clinical neurology research unit for the Sandler Neurosciences Center at Mission Bay, as well as the clinical trials program for Alzheimer's disease and frontotemporal dementia at the Memory and Aging Center.

Boxer received the Edwin Boldrey Award from the San Francisco Neurological Society in 2002 for basic research in neurological disease, the 2005 John Douglas French Alzheimer's Foundation Alzheimer's Award and a 2009 Hellman Family Foundation fellowship.

  • Education

    New York University School of Medicine, 1998

  • Residencies

    Stanford Hospital and Clinics, 2002

  • Academic Title

    Professor

We empower patients and their families to access cutting-edge diagnostic and therapeutic technologies for neurodegenerative diseases of aging.

Conditions I specialize in

Where I see patients (1)

    Selected research

    Decorative Caduceus

    Neurofilament Surveillance Project (NSP)

    To determine the longitudinal stability of plasma neurofilament light chain (NfL) measured every 3 months for 36 months in individuals at-risk for symptomatic FTLD

    Recruiting

    Decorative Caduceus

    ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

    Compare rates of change in whole brain and regional volumes between asymptomatic f-FTLD and symptomatic f- and s-FTLD, measured using MRI.

    Recruiting

    Decorative Caduceus

    Intranasal Oxytocin for Frontotemporal Dementia

    Pilot data from our two prior studies of oxytocin in FTD have driven the selection of the NPI as the primary outcome measure.

    Recruiting

    Decorative Caduceus

    4 Repeat Tauopathy Neuroimaging Initiative

    Change from baseline

    Recruiting

    Decorative Caduceus

    4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

    Change from Baseline of Tau protein distribution in the brain.

    Recruiting

    Contact me

    Providers on my team

    Share